BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 11, 2010
View Archived Issues
Reading the Tea Leaves for Interferon's Future in HCV
Last week's complete response letter for Human Genome Sciences Inc. and Novartis AG's Zalbin (albinterferon alfa-2b) came as no surprise given the hepatitis C drug's history.
Read More
Money Raised Year to Date
Read More
More Pharma-Dumped Assets Coming Back Home to Biotech
Read More
When the Going Gets Tough, the Tough Reverse Stock Split
Read More
Money Raised By Biotech in 2010
Read More
Week in Review
Read More
Word on the Street
Read More
Week in Washington
Read More
Phase I Clinical Trials Update: September 2010
Read More
FDA Approvals in September
Read More
Phase II Clinical Trials Update: September 2010
Read More
Phase III Clinical Trials Update: September 2010
Read More
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Read More
Non-U.S. Clinical Trials & Regulatory Actions: Sept. 2010
Read More
FDA Submissions, Approvals & Other Actions: Sept. 2010
Read More
Stock Gainers and Losers For The Week
Read More
BioWorld Stock Report For Public Biotechnology Companies
Read More